The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Organic whole and baby carrots have been recalled nationwide due to an E. coli outbreak that has killed at least one person, ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Cold and flu season is here, walking pneumonia is surging in kids, bird flu cases have risen, and now a more serious strain ...

Prenetics, (NASDAQ: PRE) a leading health sciences company, in partnership with David Beckham, today announced the official ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...